

## CONTENTS

NOTE TO THE READER .....	1
LIST OF PARTICIPANTS .....	3
PREAMBLE.....	7
1. Background.....	9
2. Objective and Scope .....	9
3. Selection of Topics for Monographs .....	10
4. Data for Monographs .....	11
5. The Working Group .....	11
6. Working Procedures .....	11
7. Exposure Data.....	12
8. Studies of Cancer in Humans .....	14
9. Studies of Cancer in Experimental Animals.....	17
10. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	20
11. Summary of Data Reported .....	22
12. Evaluation .....	23
13. References.....	28
GENERAL REMARKS .....	33
THE MONOGRAPHS .....	37
<b>Combined Estrogen–Progestogen Contraceptives</b> .....	39
1. Exposure Data .....	41
1.1 Introduction.....	41
1.2 Historical overview .....	42
1.3 Preparations of combined hormonal contraceptives.....	44
1.4 Patterns of use.....	45
1.4.1 Prevalence of use.....	46
1.4.2 Trends in prevalence .....	48
2. Studies of Cancer in Humans .....	50
2.1 Breast cancer.....	50
2.1.1 Background .....	50
2.1.2 Use of combined oral contraceptives and detection of breast cancer .....	50
2.1.3 Cohort studies .....	53
2.1.4 Case–control studies .....	55

2.2	Endometrial cancer .....	60
2.2.1	Descriptive studies.....	61
2.2.2	Cohort studies .....	61
2.2.3	Case-control studies .....	63
2.3	Cervical cancer .....	74
2.3.1	Introduction .....	74
2.3.2	Meta-analysis.....	76
2.3.3	Methodological considerations .....	77
2.3.4	Studies of in-situ and invasive cervical cancer in which HPV antibodies were measured.....	78
2.3.5	Studies in which cervical tissue was assayed for HPV DNA .....	80
2.3.6	Studies conducted to determine whether oral contraceptives alter the risk for progression of cervical lesions .....	84
2.4	Ovarian cancer .....	84
2.4.1	Descriptive studies.....	85
2.4.2	Cohort studies .....	85
2.4.3	Case-control studies .....	86
2.4.4	Case-control studies among breast cancer gene ( <i>BRCA1/2</i> ) carriers .....	94
2.5	Liver cancer .....	95
2.5.1	Descriptive studies.....	96
2.5.2	Cohort studies .....	96
2.5.3	Case-control studies .....	97
2.6	Colorectal cancer .....	103
2.6.1	Cohort studies .....	103
2.6.2	Case-control studies .....	106
2.7	Cutaneous malignant melanoma.....	109
2.7.1	Cohort studies .....	109
2.7.2	Case-control studies .....	111
2.7.3	Meta- and pooled analysis.....	120
2.8	Thyroid cancer .....	120
2.9	Other cancers .....	122
3.	Studies of Cancer in Experimental Animals .....	122
3.1	Estrogen-progestogen combinations .....	122
3.2	Estrogens used in combined oral contraceptives .....	131
3.2.1	Subcutaneous implantation .....	134
3.2.2	Subcutaneous injection .....	136
3.2.3	Oral administration to transgenic mice .....	137
3.3	Progestogens used in combined oral contraceptives .....	138
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	143
4.1	Absorption, distribution, metabolism and excretion.....	143
4.1.1	Ethinylestradiol and mestranol .....	144

4.1.2	Norethisterone .....	145
4.1.3	Norethisterone acetate, ethynodiol diacetate, norethynodrel and lynestrenol.....	146
4.1.4	Levonorgestrel .....	146
4.1.5	Desogestrel .....	148
4.1.6	Gestodene .....	149
4.1.7	Norgestimate .....	150
4.1.8	Newly developed progestogens .....	151
4.1.9	Interactions of other drugs with oral contraceptives .....	152
4.2	Receptor-mediated effects.....	153
4.2.1	Combined oral contraceptives .....	153
4.2.2	Oral contraception and HPV .....	159
4.2.3	Individual estrogens and progestogens .....	161
4.3	Genetic and related effects .....	164
4.3.1	Ethinylestradiol .....	164
4.3.2	Progestogens .....	166
5.	Summary of Data Reported and Evaluation .....	168
5.1	Exposure data .....	168
5.2	Human carcinogenicity data .....	169
5.3	Animal carcinogenicity data .....	171
5.4	Other relevant data .....	174
5.5	Evaluation .....	175
6.	References .....	176
	<b>Combined Estrogen–Progestogen Menopausal Therapy .....</b>	<b>203</b>
1.	Exposure Data .....	205
1.1	Introduction.....	205
1.2	Historical overview .....	206
1.3	Preparations of estrogen–progestogen menopausal therapy.....	208
1.4	Patterns of use.....	210
1.4.1	Patterns of use in 1990–2000 .....	210
1.4.2	Recent trends in hormonal menopausal therapy .....	215
2.	Studies of Cancer in Humans .....	217
2.1	Breast cancer.....	217
2.1.1	Background .....	217
2.1.2	Randomized controlled trials.....	218
2.1.3	Cohort studies .....	219
2.1.4	Case–control studies .....	228
2.2	Endometrial cancer .....	235
2.2.1	Descriptive studies.....	235
2.2.2	Randomized controlled trials.....	235
2.2.3	Cohort studies .....	235

2.2.4	Case-control studies .....	240
2.2.5	Overview .....	245
2.3	Cervical cancer .....	249
2.3.1	HPV infection .....	249
2.3.2	Cervical neoplasia .....	251
2.3.3	Overview .....	252
2.4	Ovarian cancer .....	252
2.4.1	Background .....	252
2.4.2	Randomized controlled trials.....	253
2.4.3	Cohort studies .....	253
2.4.4	Case-control studies .....	253
2.5	Liver cancer .....	255
2.6	Colorectal cancer .....	256
2.6.1	Background .....	256
2.6.2	Randomized controlled trials.....	256
2.6.3	Cohort studies .....	257
2.6.4	Case-control studies .....	259
2.7	Lung cancer.....	260
2.8	Other cancers .....	260
3.	Studies of Cancer in Experimental Animals .....	261
3.1	Oral administration .....	261
3.1.1	Mouse .....	261
3.1.2	Monkey .....	261
3.2	Administration with a known carcinogen.....	262
4.	Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms .....	263
4.1	Absorption, distribution, metabolism and excretion.....	263
4.1.1	Humans .....	263
4.1.2	Experimental systems .....	282
4.2	Receptor-mediated effects.....	282
4.2.1	Combined estrogen-progestogen therapy .....	283
4.2.2	Individual estrogens and progestogens .....	297
4.3	Side-effects other than genetic or cancer-related effects .....	300
4.3.1	Cardiovascular effects .....	300
4.3.2	Other effects.....	311
4.4	Genetic and related effects .....	317
4.4.1	Humans .....	325
4.4.2	Experimental systems .....	325
5.	Summary of Data Reported and Evaluation .....	326
5.1	Exposure data .....	326
5.2	Human carcinogenicity data .....	327
5.3	Animal carcinogenicity data .....	329

CONTENTS

ix

5.4 Other relevant data .....	329
5.5 Evaluation .....	332
6. References .....	332
ANNEXES .....	373
<b>Annex 1. Chemical and Physical Data on Compounds Used in Combined Estrogen-Progestogen Contraceptives and Hormonal Menopausal Therapy</b> .....	375
1. Estrogens .....	376
2. Progestogens .....	395
<b>Annex 2. Composition of Oral and Injectable Estrogen-Progestogen Contraceptives</b> .....	431
<b>Annex 3. Brands of Estrogen-Progestogen Contraceptives</b> .....	465
<b>Annex 4. Estrogen-Progestogen Therapies</b> .....	487
LIST OF ABBREVIATIONS .....	491
CUMULATIVE INDEX TO THE <i>MONOGRAPHS</i> SERIES .....	495



## NOTE TO THE READER

The term 'carcinogenic risk' in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer under some circumstances. The *Monographs* evaluate cancer hazards, despite the historical presence of the word 'risks' in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Carcinogen Identification and Evaluation Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Carcinogen Identification and Evaluation Group, so that corrections can be reported in future volumes.